Managing Haemophilia for Life: 5th Haemophilia Global Summit.
The 5th Haemophilia Global Summit was held in Barcelona, Spain, in September 2014. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and explored issues relevant to the practical management of haemophilia, as well as key opportunities and challenges for care in the future. The topics outlined in this supplement were selected by the Scientific Steering Committee for their relevance to improving haemophilia care globally. In this supplement from the meeting, Gerry Dolan explores pharmacokinetics and dynamics in haemophilia, and Gerry Dolan and Ian Jennings jointly address the role of the laboratory in haemophilia care. The potential benefits of low-dose prophylaxis regimens for people with haemophilia in the developing world are reviewed by Jerzy Windyga, and the question of whether 'Future haemophilia research should be undertaken in the developing world' is debated by Jerzy Windyga and Cedric Hermans. Management strategies for ankle arthropathy are discussed by Sébastien Lobet and E. Carlos Rodríguez-Merchán, and the use of ultrasound for the early detection of haemophilic arthropathy is addressed by Matteo Nicola Dario Di Minno and Víctor Jiménez-Yuste. Finally, the role of patients in the future of haemophilia care is reviewed by Brian O'Mahony.
Catholic University of Louvain, Brussels, Belgium.
Cedric
C
Hermans
St Thomas' Hospital, London, UK.
Gerry
G
Dolan
UK National External Quality Assessment Service, Sheffield, UK.
Ian
I
Jennings
Institute of Haematology and Transfusion Medicine, Warsaw, Poland.
Jerzy
J
Windyga
Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Sébastien
S
Lobet
La Paz University Hospital, Madrid, Spain.
E Carlos
EC
Rodríguez-Merchán
University of Naples Federico II, Naples, Italy.
Matteo Nicola Dario
MN
Di Minno
La Paz University Hospital, Madrid, Spain.
Víctor
V
Jiménez-Yuste
Irish Haemophilia Society, Dublin, Ireland.
Brian
B
O'Mahony
D000843:Ankle Joint / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D054869:Clinical Audit / Q000941:ethics; D002986:Clinical Trials as Topic; D003906:Developing Countries; D019468:Disease Management; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D005164:Factor IX / Q000493:pharmacokinetics* / Q000494:pharmacology; D005169:Factor VIII / Q000493:pharmacokinetics* / Q000494:pharmacology; D006207:Half-Life; D006395:Hemarthrosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006467:Hemophilia A / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D010358:Patient Participation; D018579:Patient Selection; D013030:Spain; D014463:Ultrasonography
D005169:Factor VIII; D005164:Factor IX
arthropathy; assay; global; haemophilia; prophylaxis; ultrasound